Farallon Capital Management, L.l.c.
San Francisco, CA 87 processed 13Fs on this site, 2021 Q3 to 2026 Q2
- $21.7B
- 77 holdings
- 2026 Q2
- +23.6% QoQ
- Top 5 29.9%
Farallon Capital Management's biggest moves in 2026 Q2 were opening Electronic Arts and Parabilis Medicines, adding to Immunovant and Roivant Sciences, trimming Revolution Medicines and Microsoft, and selling out of Charles Schwab and Alphabet.
AUM over time
Latest book
| RVMD, Revolution Medicines | Reduce −0.4% | 13,550,796 | $187.28 | $2.5B | −54,000 | +$1.2B | |
| EA, Electronic Arts | New | 7,919,500 | $205.04 | $1.6B | +7,919,500 | +$1.6B | |
| BBIO, Bridgebio | Add +14.7% | 10,743,063 | $74.48 | $800M | +1,377,600 | +$105M | |
| PTGX, Protagonist Therapeutics | Hold | 6,348,906 | $122.58 | $778M | — | — | |
| EXEL, Exelixis | Add +2.7% | 13,468,010 | $54.41 | $733M | +357,000 | +$170M | |
| LQDA, Liquidia | Reduce −3.4% | 8,365,038 | $79.73 | $667M | −291,000 | +$340M | |
| AMZN, Amazon | Reduce −37.6% | 2,632,994 | $238.34 | $628M | −1,585,400 | −$251M | |
| LNTH, Lantheus | Hold | 5,583,479 | $110.94 | $619M | — | — | |
| NTRA, Natera | Reduce −30.8% | 2,218,366 | $271.45 | $602M | −989,000 | −$39M | |
| UNH, UnitedHealth Group | Reduce −30.3% | 1,270,532 | $415.63 | $528M | −551,174 | +$35M | |
| TMO, Thermo Fisher Scientific | Add +19.0% | 1,049,185 | $501.36 | $526M | +167,700 | +$93M | |
| ROIV, Roivant Sciences | Add +47.9% | 14,309,000 | $35.39 | $506M | +4,634,000 | +$238M | |
| AON, Aon | Reduce −45.0% | 1,382,562 | $331.69 | $459M | −1,130,076 | −$352M | |
| BSX, Boston Scientific | Add +40.8% | 10,521,184 | $42.68 | $449M | +3,050,500 | −$20M | |
| AVGO, Broadcom | Reduce −35.3% | 1,151,800 | $377.75 | $435M | −627,700 | −$116M | |
| MSFT, Microsoft | Reduce −52.5% | 1,112,863 | $373.02 | $415M | −1,231,916 | −$453M | |
| TNGX, Tango Therapeutics | Add +35.0% | 12,277,000 | $31.26 | $384M | +3,179,589 | +$193M | |
| KKR | Reduce −11.8% | 4,118,300 | $91.78 | $378M | −553,500 | −$54M | |
| SNPS, Synopsys | Reduce −31.6% | 829,600 | $446.07 | $370M | −383,700 | −$111M | |
| BEAM, Beam Therapeutics | Add +1.0% | 10,236,396 | $34.32 | $351M | +101,700 | +$110M | |
| CRNX | Add +7.8% | 8,989,098 | $37.42 | $336M | +651,000 | +$34M | |
| GRAL, Grail | Add +27.9% | 4,161,584 | $68.27 | $284M | +907,900 | +$116M | |
| WAB, Wabtec | Reduce −44.4% | 894,503 | $269.60 | $241M | −714,900 | −$161M | |
| IMVT, Immunovant | Add +275.5% | 5,805,000 | $38.53 | $224M | +4,259,000 | +$185M | |
| TWST, Twist Bioscience | Add +49.6% | 2,136,400 | $102.88 | $220M | +708,750 | +$152M | |
| AGIO, Agios Pharmaceuticals | Add +4.1% | 5,917,400 | $37.11 | $220M | +233,400 | +$27M | |
| ARMK, Aramark | Reduce −40.9% | 3,625,731 | $56.90 | $206M | −2,509,700 | −$42M | |
| BIDU, Baidu | Add +171.3% | 1,203,785 | $114.29 | $138M | +760,000 | +$88M | |
| NVO, Novo Nordisk | Add +234.9% | 2,619,000 | $47.94 | $126M | +1,837,000 | +$97M | |
| ACHC | Add +143.0% | 4,220,800 | $29.53 | $125M | +2,484,000 | +$84M | |
| BTSG, Brightspring Health Services | Add +7.2% | 1,732,800 | $69.74 | $121M | +115,800 | +$52M | |
| AZN, AstraZeneca | Add +153.4% | 574,000 | $189.62 | $109M | +347,501 | +$64M | |
| JNJ, Johnson & Johnson | Add +175.7% | 408,000 | $253.97 | $104M | +260,000 | +$67M | |
| PBLS, Parabilis Medicines | New | 2,368,200 | $27.37 | $65M | +2,368,200 | +$65M | |
| NVS, Novartis | New | 363,000 | $156.72 | $57M | +363,000 | +$57M | |
| GH, Guardant Health | Add +3927.5% | 322,200 | $150.03 | $48M | +314,200 | +$48M | |
| AVTX, Avalo Therapeutics | Add +172.7% | 2,498,000 | $18.48 | $46M | +1,582,000 | +$32M | |
| JOYY | Add +20.9% | 699,200 | $65.99 | $46M | +121,000 | +$12M | |
| ASMB, Assembly Biosciences | Add +30.7% | 1,604,590 | $27.48 | $44M | +377,000 | +$10M | |
| ENTA, Enanta Pharmaceuticals | Reduce −15.8% | 2,418,202 | $14.58 | $35M | −453,660 | −$1M | |
| MAZE, Maze Therapeutics | Add +197.0% | 1,107,814 | $29.84 | $33M | +734,814 | +$22M | |
| MRK, Merck | Reduce −44.9% | 199,000 | $128.50 | $26M | −162,000 | −$18M | |
| WRBY, Warby Parker | New | 828,000 | $30.34 | $25M | +828,000 | +$25M | |
| PCSC, Perceptive Cap Solutions | Hold | 2,250,000 | $10.88 | $24M | — | — | |
| KLRA, Kailera Therapeutics | New | 1,100,000 | $22.03 | $24M | +1,100,000 | +$24M | |
| RIO, Rio Tinto | Add +241.0% | 183,475 | $94.93 | $17M | +129,675 | +$12M | |
| AXTA, Axalta Coating Systems | New | 478,000 | $34.22 | $16M | +478,000 | +$16M | |
| ABVX, Abivax | Add +6000.0% | 122,000 | $133.26 | $16M | +120,000 | +$16M | |
| VNET, Vnet Group | Add +219.6% | 1,992,000 | $8.04 | $16M | +1,368,653 | +$11M | |
| NTES, NetEase | Reduce −57.6% | 123,500 | $128.14 | $16M | −167,719 | −$17M | |
| BIIB, Biogen | New | 71,000 | $216.06 | $15M | +71,000 | +$15M | |
| TSHA, Taysha Gene Therapies | New | 2,250,000 | $6.81 | $15M | +2,250,000 | +$15M | |
| MOBI, Mobia Medical | New | 1,128,557 | $13.40 | $15M | +1,128,557 | +$15M | |
| NERV, Minerva Neurosciences | Hold | 2,365,000 | $5.55 | $13M | — | — | |
| ALMR, Alamar Biosciences | New | 462,900 | $27.09 | $13M | +462,900 | +$13M | |
| ALVO, Alvotech | Add +1332.2% | 2,859,675 | $3.69 | $11M | +2,660,000 | +$9.9M | |
| BBNX, Beta Bionics | Reduce −83.5% | 595,000 | $15.67 | $9.3M | −3,012,920 | −$27M | |
| IFRX, Inflarx | New | 3,325,000 | $2.24 | $7.4M | +3,325,000 | +$7.4M | |
| SMG, Scotts Miracle-Gro | New | 88,000 | $68.11 | $6M | +88,000 | +$6M | |
| WAY, Waystar | New | 264,900 | $20.53 | $5.4M | +264,900 | +$5.4M | |
| BC, Brunswick | New | 61,000 | $84.24 | $5.1M | +61,000 | +$5.1M | |
| GNTX, Gentex | New | 199,000 | $25.27 | $5M | +199,000 | +$5M | |
| IDXX, Idexx Laboratories | New | 9,000 | $526.44 | $4.7M | +9,000 | +$4.7M | |
| PRME, Prime Medicine | Hold | 1,240,843 | $3.69 | $4.6M | — | — | |
| CMC, Commercial Metals | New | 67,000 | $62.75 | $4.2M | +67,000 | +$4.2M | |
| JATT, Jatt II Acquisition | New | 300,000 | $11.36 | $3.4M | +300,000 | +$3.4M | |
| SGMT, Sagimet Biosciences | New | 415,000 | $7.73 | $3.2M | +415,000 | +$3.2M | |
| SMC, Summit Midstream | Hold | 58,214 | $28.48 | $1.7M | — | — | |
| TEVA, Teva Pharmaceutical Industries | Reduce −88.7% | 40,000 | $33.88 | $1.4M | −314,000 | −$9.3M | |
| COGT, Cogent Biosciences | Hold | 17,000 | $38.70 | $658K | — | — | |
| ANNA, Aleanna | Hold | 78,400 | $2.90 | $227K | — | — | |
| WELL, Welltower | Reduce −99.5% | 1,000 | $226.97 | $227K | −199,000 | −$39M | |
| PACB | Reduce −89.5% | 14,200 | $1.68 | $24K | −120,800 | −$154K | |
| GERN, Geron | Reduce −66.5% | 14,400 | $1.28 | $18K | −28,600 | −$46K | |
| CGC, Canopy Growth | Reduce −40.0% | 18,000 | $0.9500 | $17K | −12,000 | −$11K | |
| RANI, Rani Therapeutics | Reduce −73.5% | 20,700 | $0.7604 | $16K | −57,300 | −$42K | |
| BYND, Beyond Meat | Hold | 19,000 | $0.7500 | $14K | — | — |
Showing top 50 of 77 by value
Exits / last held
Gone since 2026 Q1, shown at their last reported size.
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| SCHW, Charles Schwab | Exit | 0 | $93.98 | $372M | −3,955,657 | −$372M | |
| GOOG, Alphabet | Exit | 0 | $286.86 | $286M | −996,231 | −$286M | |
| V, Visa | Exit | 0 | $302.24 | $254M | −840,710 | −$254M | |
| DIS, Disney | Exit | 0 | $96.38 | $231M | −2,401,591 | −$231M | |
| MA, Mastercard | Exit | 0 | $499.66 | $217M | −435,071 | −$217M | |
| MCK, McKesson | Exit | 0 | $865.36 | $203M | −234,300 | −$203M | |
| CNTA, Centessa Pharmaceuticals | Exit | 0 | $39.72 | $191M | −4,809,000 | −$191M | |
| TYRA, Tyra Biosciences | Exit | 0 | $38.30 | $137M | −3,580,818 | −$137M | |
| THC, Tenet Healthcare | Exit | 0 | $188.71 | $85M | −452,153 | −$85M | |
| CAH, Cardinal Health | Exit | 0 | $211.31 | $78M | −368,000 | −$78M | |
| PCVX, Vaxcyte | Exit | 0 | $58.11 | $73M | −1,261,000 | −$73M | |
| DNTH, Dianthus Therapeutics | Exit | 0 | $83.92 | $70M | −836,000 | −$70M | |
| CGON, CG Oncology | Exit | 0 | $67.68 | $46M | −674,000 | −$46M | |
| BITW, Bitwise 10 Crypto Index ETF | Exit | 0 | $44.61 | $27M | −603,000 | −$27M | |
| RPRX | Exit | 0 | $47.97 | $24M | −493,000 | −$24M | |
| CECO, Ceco Environmental | Exit | 0 | $59.58 | $14M | −234,000 | −$14M | |
| GDS, GDS Holdings | Exit | 0 | $40.29 | $12M | −292,000 | −$12M | |
| FORM, Formfactor | Exit | 0 | $96.99 | $5.5M | −56,500 | −$5.5M | |
| MTZ, Mastec | Exit | 0 | $321.76 | $5.5M | −17,000 | −$5.5M | |
| ENTG, Entegris | Exit | 0 | $117.23 | $5.3M | −45,500 | −$5.3M | |
| C, Citigroup | Exit | 0 | $113.40 | $5.3M | −47,000 | −$5.3M | |
| H, Hyatt Hotels | Exit | 0 | $143.78 | $5.2M | −36,000 | −$5.2M | |
| WST, Western Alliance Bancorp | Exit | 0 | $70.85 | $5.2M | −73,000 | −$5.2M | |
| TKR, Timken | Exit | 0 | $100.57 | $5.1M | −51,000 | −$5.1M | |
| FLEX, Flextronics International | Exit | 0 | $65.46 | $5.1M | −78,000 | −$5.1M | |
| SPGI, S&P Global | Exit | 0 | $425.33 | $5.1M | −12,000 | −$5.1M | |
| LFUS, Littelfuse | Exit | 0 | $339.33 | $5.1M | −15,000 | −$5.1M | |
| PIPR, Piper Sandler Companies | Exit | 0 | $76.55 | $5.1M | −66,000 | −$5.1M | |
| AIR, Aar | Exit | 0 | $109.46 | $5M | −46,000 | −$5M | |
| GTX, Garrett Motion | Exit | 0 | $18.17 | $5M | −275,000 | −$5M | |
| ROL, Rollins | Exit | 0 | $53.41 | $5M | −93,000 | −$5M | |
| AFRM, Affirm | Exit | 0 | $45.82 | $4.9M | −108,000 | −$4.9M | |
| INTR, Inter And | Exit | 0 | $7.96 | $4.9M | −614,500 | −$4.9M | |
| CMI, Cummins | Exit | 0 | $538.00 | $4.8M | −9,000 | −$4.8M | |
| FISV, Fiserv | Exit | 0 | $55.80 | $4.8M | −86,000 | −$4.8M | |
| VRT, Vertiv | Exit | 0 | $250.58 | $4.8M | −19,000 | −$4.8M | |
| AMKR, Amkor Technology | Exit | 0 | $45.03 | $4.7M | −104,000 | −$4.7M | |
| RNA, Atrium Therapeutics | Exit | 0 | $13.37 | $4.7M | −349,360 | −$4.7M | |
| GFS, Globalfoundries | Exit | 0 | $44.48 | $4.7M | −105,000 | −$4.7M | |
| MOH, Molina Healthcare | Exit | 0 | $133.31 | $4.7M | −35,000 | −$4.7M | |
| IRD, Opus Genetics | Exit | 0 | $4.55 | $4.6M | −1,000,000 | −$4.6M | |
| TENB, Tenable | Exit | 0 | $16.91 | $4.5M | −265,000 | −$4.5M | |
| NOW, ServiceNow | Exit | 0 | $104.56 | $4.3M | −41,000 | −$4.3M | |
| MDGL, Madrigal Pharmaceuticals | Exit | 0 | $523.35 | $1.7M | −3,319 | −$1.7M | |
| CAPR | Exit | 0 | $30.39 | $1.2M | −41,000 | −$1.2M | |
| ARWR, Arrowhead Pharmaceuticals | Exit | 0 | $62.72 | $991K | −15,800 | −$991K | |
| ALKS, Alkermes | Exit | 0 | $35.34 | $735K | −20,800 | −$735K | |
| AXSM, Axsome Therapeutics | Exit | 0 | $169.00 | $676K | −4,000 | −$676K | |
| ARQT, Arcutis Biotherapeutics | Exit | 0 | $23.58 | $613K | −26,000 | −$613K | |
| CELC, Celcuity | Exit | 0 | $114.25 | $457K | −4,000 | −$457K | |
| LIVN, Livanova | Exit | 0 | $63.50 | $381K | −6,000 | −$381K | |
| TERN, Terns Pharmaceuticals | Exit | 0 | $52.71 | $369K | −7,000 | −$369K | |
| IONS, Ionis Pharmaceuticals | Exit | 0 | $75.00 | $360K | −4,800 | −$360K | |
| TVTX, Travere Therapeutics | Exit | 0 | $29.75 | $357K | −12,000 | −$357K | |
| GMED, Globus Medical | Exit | 0 | $86.25 | $345K | −4,000 | −$345K | |
| SRRK, Scholar Rock | Exit | 0 | $49.14 | $344K | −7,000 | −$344K | |
| ONC, Beone Medicines | Exit | 0 | $297.27 | $327K | −1,100 | −$327K | |
| WGS, Genedx | Exit | 0 | $64.20 | $321K | −5,000 | −$321K | |
| COR, Cencora | Exit | 0 | $314.00 | $314K | −1,000 | −$314K | |
| NUVL, Nuvalent | Exit | 0 | $102.33 | $307K | −3,000 | −$307K | |
| PGNY, Progyny | Exit | 0 | $17.00 | $306K | −18,000 | −$306K | |
| STOK, Stoke Therapeutics | Exit | 0 | $32.56 | $293K | −9,000 | −$293K | |
| ERAS, Erasca | Exit | 0 | $16.17 | $291K | −18,000 | −$291K | |
| EHC, Encompass Health | Exit | 0 | $96.67 | $290K | −3,000 | −$290K | |
| NKTR, Nektar Therapeutics | Exit | 0 | $72.00 | $288K | −4,000 | −$288K | |
| GKOS, Glaukos | Exit | 0 | $107.69 | $280K | −2,600 | −$280K | |
| MIRM, Mirum Pharmaceuticals | Exit | 0 | $92.33 | $277K | −3,000 | −$277K | |
| SBRA, Sabra Health Care REIT | Exit | 0 | $19.21 | $269K | −14,000 | −$269K | |
| KRYS, Krystal Biotech | Exit | 0 | $258.00 | $258K | −1,000 | −$258K | |
| OMER, Omeros | Exit | 0 | $10.57 | $243K | −23,000 | −$243K | |
| ALMS, Alumis | Exit | 0 | $22.00 | $242K | −11,000 | −$242K | |
| APLS, Apellis Pharmaceuticals | Exit | 0 | $40.17 | $241K | −6,000 | −$241K | |
| HQY, Healthequity | Exit | 0 | $83.57 | $234K | −2,800 | −$234K | |
| SNDX, Syndax Pharmaceuticals | Exit | 0 | $23.40 | $234K | −10,000 | −$234K | |
| FOLD, Amicus | Exit | 0 | $14.44 | $231K | −16,000 | −$231K | |
| QURE, Uniqure | Exit | 0 | $16.36 | $229K | −14,000 | −$229K | |
| BCRX, Biocryst Pharmaceuticals | Exit | 0 | $9.50 | $228K | −24,000 | −$228K | |
| GRFS, Grifols | Exit | 0 | $8.04 | $225K | −28,000 | −$225K | |
| VCYT, Veracyte | Exit | 0 | $32.14 | $225K | −7,000 | −$225K | |
| GEHC, GE HealthCare | Exit | 0 | $71.33 | $214K | −3,000 | −$214K | |
| HIMS, Hims & Hers Health | Exit | 0 | $20.80 | $208K | −10,000 | −$208K | |
| BLTE, Belite Bio | Exit | 0 | $159.23 | $207K | −1,300 | −$207K | |
| MMSI, Merit Medical Systems | Exit | 0 | $69.00 | $207K | −3,000 | −$207K | |
| SUPN, Supernus Pharmaceuticals | Exit | 0 | $51.75 | $207K | −4,000 | −$207K | |
| HR, Healthcare Realty Trust | Exit | 0 | $17.00 | $204K | −12,000 | −$204K | |
| URGN, Urogen | Exit | 0 | $18.00 | $198K | −11,000 | −$198K | |
| VIR, Vir Biotechnology | Exit | 0 | $8.95 | $197K | −22,000 | −$197K | |
| PGEN, Precigen | Exit | 0 | $3.88 | $194K | −50,000 | −$194K | |
| SDGR, Schrodinger | Exit | 0 | $11.35 | $193K | −17,000 | −$193K | |
| DYN, Dyne Therapeutics | Exit | 0 | $18.10 | $181K | −10,000 | −$181K | |
| NVAX, Novavax | Exit | 0 | $8.14 | $179K | −22,000 | −$179K | |
| SLS | Exit | 0 | $4.22 | $169K | −40,000 | −$169K | |
| ADPT | Exit | 0 | $13.91 | $153K | −11,000 | −$153K | |
| OCUL, Ocular Therapeutix | Exit | 0 | $8.44 | $152K | −18,000 | −$152K | |
| NEO, Neogenomics | Exit | 0 | $7.42 | $141K | −19,000 | −$141K | |
| ARDX, Ardelyx | Exit | 0 | $6.00 | $138K | −23,000 | −$138K | |
| OSCR, Oscar Health | Exit | 0 | $11.45 | $126K | −11,000 | −$126K | |
| NUVB, Nuvation Bio | Exit | 0 | $4.28 | $124K | −29,000 | −$124K | |
| IOVA, Iovance Biotherapeutics | Exit | 0 | $3.50 | $91K | −26,000 | −$91K | |
| ALT, Altimmune | Exit | 0 | $3.08 | $85K | −27,600 | −$85K | |
| CCCC, C4 Therapeutics | Exit | 0 | $2.64 | $74K | −28,000 | −$74K | |
| TVRD, Tvardi Therapeutics | Exit | 0 | $3.17 | $68K | −21,438 | −$68K | |
| IRWD, Ironwood Pharmaceuticals | Exit | 0 | $3.54 | $46K | −13,000 | −$46K | |
| EVH, Evolent Health | Exit | 0 | $2.29 | $32K | −14,000 | −$32K |
Filings history
20 periods, with AUM normalized
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 89 | $21.7B | +23.6% | 13F-HR | 8/14/2026 | 000090883426000432 |
| 2026 Q1 | 1 | $1.5B | — | new holds | 8/14/2026 | 000090883426000434 |
| 2026 Q1 | 172 | $17.5B | −17.2% | 13F-HR | 5/15/2026 | 000090883426000240 |
| 2025 Q4 | 1 | $1B | — | new holds | 8/14/2026 | 000090883426000433 |
| 2025 Q4 | 2 | $884M | — | new holds | 5/15/2026 | 000090883426000241 |
| 2025 Q4 | 151 | $21.2B | −13.2% | 13F-HR | 2/17/2026 | 000090883426000087 |
| 2025 Q3 | 144 | $24.4B | — | RESTATEMENT | 2/17/2026 | 000090883426000086 |
| 2025 Q3 | 144 | $24.4B | +5.4% | 13F-HR | 11/14/2025 | 000090883425000353 |
| 2025 Q2 | 1 | $140M | — | new holds | 2/17/2026 | 000090883426000085 |
| 2025 Q2 | 3 | $483M | — | new holds | 11/14/2025 | 000090883425000352 |
| 2025 Q2 | 141 | $23.2B | +29.2% | 13F-HR | 8/14/2025 | 000090883425000248 |
| 2025 Q1 | 1 | $274M | — | new holds | 2/17/2026 | 000090883426000084 |
| 2025 Q1 | 3 | $416M | — | new holds | 11/14/2025 | 000090883425000351 |
| 2025 Q1 | 7 | $2.2B | — | new holds | 8/14/2025 | 000090883425000247 |
| 2025 Q1 | 135 | $17.9B | −9.0% | 13F-HR | 5/15/2025 | 000090883425000177 |
| 2024 Q4 | 1 | $85M | — | new holds | 2/17/2026 | 000090883426000083 |
| 2024 Q4 | 2 | $349M | — | new holds | 11/14/2025 | 000090883425000350 |
| 2024 Q4 | 6 | $2.3B | — | new holds | 8/14/2025 | 000090883425000246 |
| 2024 Q4 | 4 | $333M | — | new holds | 5/15/2025 | 000090883425000180 |
| 2024 Q4 | 138 | $19.7B | −3.5% | 13F-HR | 2/14/2025 | 000090883425000081 |
| 2024 Q3 | 1 | $145M | — | new holds | 11/14/2025 | 000090883425000349 |
| 2024 Q3 | 6 | $1.5B | — | new holds | 8/14/2025 | 000090883425000243 |
| 2024 Q3 | 3 | $216M | — | new holds | 5/15/2025 | 000090883425000179 |
| 2024 Q3 | 2 | $544M | — | new holds | 2/14/2025 | 000090883425000080 |
| 2024 Q3 | 153 | $20.4B | −3.6% | 13F-HR | 11/14/2024 | 000090883424000307 |
| 2024 Q2 | 1 | $120M | — | new holds | 11/14/2025 | 000090883425000348 |
| 2024 Q2 | 5 | $1.2B | — | new holds | 8/14/2025 | 000090883425000245 |
| 2024 Q2 | 1 | $199M | — | new holds | 5/15/2025 | 000090883425000178 |
| 2024 Q2 | 2 | $452M | — | new holds | 2/14/2025 | 000090883425000079 |
| 2024 Q2 | 1 | $149M | — | new holds | 11/14/2024 | 000090883424000324 |
| 2024 Q2 | 157 | $21.2B | −4.2% | 13F-HR | 8/14/2024 | 000090883424000200 |
| 2024 Q1 | 1 | $93M | — | new holds | 11/14/2025 | 000090883425000347 |
| 2024 Q1 | 4 | $1.2B | — | new holds | 8/14/2025 | 000090883425000244 |
| 2024 Q1 | 2 | $159M | — | new holds | 2/14/2025 | 000090883425000078 |
| 2024 Q1 | 1 | $45M | — | new holds | 8/14/2024 | 000090883424000202 |
| 2024 Q1 | 167 | $22.1B | — | RESTATEMENT | 5/24/2024 | 000090883424000159 |
| 2024 Q1 | 167 | $22.1B | +9.8% | 13F-HR | 5/15/2024 | 000090883424000135 |
| 2023 Q4 | 1 | $65M | — | new holds | 11/14/2025 | 000090883425000346 |
| 2023 Q4 | 2 | $548M | — | new holds | 8/14/2025 | 000090883425000250 |
| 2023 Q4 | 5 | $1.1B | — | new holds | 5/15/2024 | 000090883424000141 |
| 2023 Q4 | 150 | $20.1B | +1.0% | 13F-HR | 2/14/2024 | 000090883424000070 |
| 2023 Q3 | 1 | $40M | — | new holds | 11/14/2025 | 000090883425000345 |
| 2023 Q3 | 1 | $40M | — | new holds | 5/15/2024 | 000090883424000138 |
| 2023 Q3 | 2 | $1.4B | — | new holds | 2/14/2024 | 000090883424000077 |
| 2023 Q3 | 1 | $1.9B | — | new holds | 2/12/2024 | 000090883424000049 |
| 2023 Q3 | 159 | $20B | +11.5% | 13F-HR | 11/14/2023 | 000090883423000150 |
| 2023 Q2 | 2 | $669M | — | new holds | 2/14/2024 | 000090883424000076 |
| 2023 Q2 | 5 | $1.4B | — | new holds | 11/14/2023 | 000090883423000157 |
| 2023 Q2 | 1 | $1.2B | — | new holds | 10/26/2023 | 000090883423000134 |
| 2023 Q2 | 165 | $17.9B | +1.3% | 13F-HR | 8/14/2023 | 000090883423000109 |
| 2023 Q1 | 2 | $234M | — | new holds | 2/14/2024 | 000090883424000075 |
| 2023 Q1 | 3 | $389M | — | new holds | 11/14/2023 | 000090883423000156 |
| 2023 Q1 | 1 | $15M | — | new holds | 8/14/2023 | 000090883423000110 |
| 2023 Q1 | 187 | $17.7B | +15.8% | 13F-HR | 5/15/2023 | 000117570723000127 |
| 2022 Q4 | 1 | $171M | — | new holds | 2/14/2024 | 000090883424000074 |
| 2022 Q4 | 3 | $485M | — | new holds | 11/14/2023 | 000090883423000155 |
| 2022 Q4 | 7 | $1B | — | new holds | 5/15/2023 | 000117570723000136 |
| 2022 Q4 | 232 | $15.3B | −9.3% | 13F-HR | 2/14/2023 | 000117570723000051 |
| 2022 Q3 | 1 | $125M | — | new holds | 2/14/2024 | 000090883424000073 |
| 2022 Q3 | 3 | $415M | — | new holds | 11/14/2023 | 000090883423000154 |
| 2022 Q3 | 5 | $411M | — | new holds | 5/15/2023 | 000117570723000135 |
| 2022 Q3 | 4 | $434M | — | new holds | 2/14/2023 | 000090966123000005 |
| 2022 Q3 | 298 | $16.8B | +3.5% | 13F-HR | 11/14/2022 | 000156761922019851 |
| 2022 Q2 | 1 | $115M | — | new holds | 2/14/2024 | 000090883424000081 |
| 2022 Q2 | 3 | $411M | — | new holds | 11/14/2023 | 000090883423000153 |
| 2022 Q2 | 2 | $337M | — | new holds | 5/15/2023 | 000117570723000134 |
| 2022 Q2 | 3 | $136M | — | new holds | 2/14/2023 | 000090966123000003 |
| 2022 Q2 | 9 | $1.2B | — | new holds | 11/14/2022 | 000156761922019862 |
| 2022 Q2 | 297 | $16.3B | −13.7% | 13F-HR | 8/15/2022 | 000156761922015953 |
| 2022 Q1 | 1 | $268M | — | new holds | 11/14/2023 | 000090883423000152 |
| 2022 Q1 | 1 | $314M | — | new holds | 5/15/2023 | 000117570723000133 |
| 2022 Q1 | 1 | $27M | — | new holds | 2/14/2023 | 000090966123000002 |
| 2022 Q1 | 3 | $186M | — | new holds | 11/14/2022 | 000156761922019864 |
| 2022 Q1 | 8 | $1.1B | — | new holds | 8/15/2022 | 000156761922015972 |
| 2022 Q1 | 307 | $18.8B | +0.4% | 13F-HR | 5/16/2022 | 000156761922010736 |
| 2021 Q4 | 1 | $227M | — | new holds | 5/15/2023 | 000117570723000132 |
| 2021 Q4 | 1 | $7M | — | new holds | 11/14/2022 | 000156761922019852 |
| 2021 Q4 | 1 | $115M | — | new holds | 8/15/2022 | 000156761922015968 |
| 2021 Q4 | 2 | $98M | — | new holds | 5/19/2022 | 000156761922011257 |
| 2021 Q4 | 6 | $833M | — | new holds | 5/16/2022 | 000156761922010757 |
| 2021 Q4 | 289 | $18.7B | −5.1% | 13F-HR | 2/14/2022 | 000156761922003965 |
| 2021 Q3 | 1 | $182M | — | new holds | 5/15/2023 | 000117570723000131 |
| 2021 Q3 | 1 | $105M | — | new holds | 8/15/2022 | 000156761922015964 |
| 2021 Q3 | 1 | $57M | — | new holds | 5/19/2022 | 000156761922011256 |
| 2021 Q3 | 3 | $998M | — | new holds | 5/16/2022 | 000156761922010753 |
| 2021 Q3 | 2 | $344M | — | new holds | 2/14/2022 | 000156761922003981 |
| 2021 Q3 | 293 | $19.7B | — | 13F-HR | 11/15/2021 | 000095012321015168 |
About
Farallon Capital Management, L.l.c.
87 processed 13Fs on this site, 2021 Q3 to 2026 Q2